Passage Bio, Inc.
A clinical-stage gene therapy company developing one-time treatments for rare brain and nervous-system diseases. Founded in 2019 as a spinout of the University of Pennsylvania's Gene Therapy Program, it builds on the work of gene-therapy pioneer James Wilson. Its name comes from "passaging" — the lab process of growing and purifying the harmless viruses that carry therapeutic genes into cells. Its lead programs target rare disorders such as GM1 gangliosidosis and Krabbe disease.
Sold 1.97M
Bought 1.04M
Granted 55.0K · Sold 17.5K
Granted 50.0K · Sold 15.8K
Granted 10.0K · Sold 4.1K
Granted 47.0K · Sold 17.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Orbimed Advisors LLC +1 co-filer10% owner · 25 transactions | — | 12.72Mas of Jun 2025 | — | — | 1.97M |
| Lynx1 Capital Management LP +1 co-filer10% owner · 11 transactions | — | 673.8K | — | 1.04M | — |
| Forman Mark SCHIEF MEDICAL OFFICER · 4 transactions | — | 48.6Kas of Feb 2024 | 55.0K | — | 17.5K |
| Cale Edgar B.GC & Corporate Secretary · 2 transactions | +866.5% | 46.0Kas of Jan 2024 | 50.0K | — | 15.8K |
| Chou WilliamPRESIDENT AND CEO, Director · 2 transactions | — | 6.5K | 10.0K | — | 4.1K |
| Borthwick KathleenCFO · 8 transactions | — | 5.4K | 47.0K | — | 17.4K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -981.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.